Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.59 |
| ▸ | MEN1 | O00255 | 9/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | CRHBP | P24387 | 2/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4560197 | 0.88 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6760385 | 0.87 | ALDH1A1 (0.51) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6760390 | 0.86 | LMNA (0.57) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL17610507 | 0.85 | MGAM (0.54) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL22573586 | 0.85 | NPC1 (0.50) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL22573442 | 0.84 | MAP4K4 (0.51) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL22573798 | 0.83 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL22712505 | 0.82 | NPC1 (0.50) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11256378 | 0.81 | SMN1; SMN2 (0.56) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL11257381 | 0.81 | SMN1; SMN2 (0.56) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| CN-1296346-C | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-01-24 | — | — | CN | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
| CN-1491208-A | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical | ������ҽҩ�¹�����˾ | 2004-04-21 | — | — | CN | disclosed |
| CN-1185737-A | Isothiazolones | WARNER LAMBERT CO (US) | 1998-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | ALDH1A1 3019/4885MAPT 1/4885SMN1; SMN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.